NEW YORK, May 19, 2017 /PRNewswire/ --
For today, Stock-Callers.com scans the performances of Baxter InternationalInc. (NYSE: BAX), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), OraSure Technologies Inc. (NASDAQ: OSUR), and Glaukos Corp. (NYSE: GKOS). According to an IBISWorld report, changing demographics, healthcare reform, and product innovation will shape the Medical
On Thursday, shares in Deerfield, Illinois headquartered Baxter International Inc. climbed 0.37%, ending the day at $57.07. The stock recorded a trading volume of 3.27 million shares, which was above its three months average volume of 3.09 million shares. The Company's shares have advanced 8.27% in the last one month, 15.78% over the previous three months, and 29.04% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.63% and 17.56%, respectively. Moreover, shares of Baxter, which provides a portfolio of renal and hospital products, have a Relative Strength Index (RSI) of 71.53.
On April 27th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $55 a share to $58 a share.
On May 09th, 2017, Baxter announced that it has been named by Forbes magazine as one of America's Best Large Employers in 2017. This marks the third consecutive year that the Company has been named to the prestigious list. BAX complete research report is just a click away and free at:
Shares in York, Pennsylvania headquartered DENTSPLY SIRONA Inc. ended the day 0.51% higher at $61.66 with a total trading volume of 996,945 shares. In the previous three months and on an YTD basis, the stock has gained 1.66% and 6.96%, respectively. The Company's shares are trading above their 200-day moving average by 2.34%. Furthermore, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have an RSI of 41.75.
On May 09th, 2017, DENTSPLY SIRONA announced its financial results for the three months ended March 31st, 2017. Revenues for Q1 2017 were $900.5 million, up 16.6% compared to Q1 2016; sales of the combined businesses declined 2.2%, excluding the effect of exchange rates; GAAP EPS was $0.26, down 64%; and non-GAAP adjusted EPS was $0.49, a decrease of 29%. Management also reiterated its EPS guidance for 2017 in the range of $2.80 to $2.90 per diluted share. The complimentary report on XRAY can be downloaded at:
At the close of trading on Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. finished 1.03% lower at $14.35 with a total trading volume of 1.02 million shares. The stock has advanced 14.71% in the last one month, 29.28% over the previous three months, and 63.44% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 11.86% and 48.75%, respectively. Additionally, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have an RSI of 57.61.
On May 16th, 2017, OraSure Technologies announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS Global Healthcare Conference on May 23rd, 2017 at approximately 8:30 a.m. ET in New York. The conference will be simultaneously webcast on the Company's website. Sign up for your complimentary research report on OSUR at:
San Clemente, California headquartered Glaukos Corp.'s shares recorded a trading volume of 755,533 shares at the end of yesterday's session, which was above their three months average volume of 646,620 shares. The stock closed the day 0.03% lower at $37.29. The Company's shares have advanced 8.72% on an YTD basis. The stock is trading below its 200-day moving average by 3.89%. Additionally, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have an RSI of 28.79.
On May 03rd, 2017, Glaukos announced the completion of patient enrollment in the US Investigational New Drug Phase II study of its Travoprost Intraocular Implant with the iDose™ delivery system in patients with glaucoma. Implanted during a micro-invasive procedure, the iDose is designed to continuously elute therapeutic levels of medication from within the eye for extended periods of time. Get free access to your research report on GKOS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...
Brugada syndrome is a rare genetic heart condition that affects the way electrical signals pass ...
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in ...View All